Skip to content
value.today
Moderna Therapeutics, Inc. logo

Moderna Therapeutics, Inc.

Formerly MT NewCo, Inc.

Total raised
$451 M
1 round on record
Latest round
$451 M
Aug 2016
First round on record
Aug 2016
Today
Went public
See the company page

Moderna Therapeutics, Inc. is listed today as Moderna, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Moderna Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2016$451 MNo. 1$250 million to $1 billion

Moderna Therapeutics, Inc.: Raise no. 1, Aug 2016

Investors in this round

72 investors had bought by the notice of Aug 24, 2016: 72 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Moderna Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$451 M of $600 M offered; $149 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James R. Kasinger · Executive Officer
  • Lorence Kim · Executive Officer
  • Stephane Bancel · Executive Officer, Director
  • Stephen Hoge · Executive Officer
  • Elizabeth Nabel · Director
  • Henri Termeer · Director
  • John Mendlein · Director
  • Lee Babiss · Director
  • Noubar Afeyan · Director
  • Peter Hutt · Director
  • Robert Langer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James R. Kasinger, General Counsel and Secretary. Source: SEC Form D, newest notice filed Aug 24, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Moderna, Inc., its revenue in fiscal 2025 came from these product and service lines: Net product sales $1.82 billion (94%), COVID $1.81 billion (93%), Other revenue $126 million (6%), Stand-ready manufacturing revenue $80 million (4%), Grant revenue $22 million (1%).

    Annual report (SEC XBRL) · Dec 2025

  • Moderna Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2016).

    SEC Form D · Aug 2016

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2016

Products#

  • mRNA-1273 vaccine

From the company page of Moderna, Inc..

Services#

No services of Moderna Therapeutics, Inc. are on record.

Investors#

11 named in official filings. Open an investor to see everything it has backed.

Investors in Moderna Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Elizabeth G. NabelPersonnot statednot statedHeld Series G preferred stock, director (Form 3, 2018)SEC Form 3
Flagship Pioneering, LLCFund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship VentureLabs IV, LLCVenture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship Ventures Fund IV General Partner LLCVenture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3
Flagship Ventures Fund IV, L.P.Venture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship Ventures Fund IV-Rx, L.P.Venture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Israel RuizPersonnot statednot statedHeld Series G preferred stock, director (Form 3, 2018)SEC Form 3
Lorence H. KimPersonnot statednot statedHeld Series E preferred stock (Form 3, 2018)SEC Form 3
Robert LangerPersonnot statednot statedHeld Series G preferred stock, director (Form 3, 2018)SEC Form 3
Stephen BerensonPersonnot statednot statedHeld Series G preferred stock, director (Form 3, 2018)SEC Form 3
Stephen HogePersonnot statednot statedHeld Series E preferred stock (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 72 investors.

Largest shareholders today

Institutions holding Moderna, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Moderna Therapeutics, Inc.
NameRoleNamed in
James R. KasingerExecutive officerAug 2016
Lorence KimExecutive officerAug 2016
Stephane BancelExecutive officerAug 2016
Stephen HogeExecutive officerAug 2016
Elizabeth NabelDirectorAug 2016
Henri TermeerDirectorAug 2016
John MendleinDirectorAug 2016
Lee BabissDirectorAug 2016
Noubar AfeyanDirectorAug 2016
Peter HuttDirectorAug 2016
Robert LangerDirectorAug 2016
Stephane BancelDirectorAug 2016

About

American biotechnology company.

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.